EPO and chronic kidney disease: Third, with regard to acceptability, although our results showed that in DD-CKD patients, the proportions of AEs and SAEs associated with the different HIF-PHIs were no differ from ESAs with the selected dose-adjusted mode, roxadustat and vadadustat showed a higher risk of increasing the discontinuation rate than ESAs, which ranged from rhEPO and DPO to MPG-EPO.